PMA device
nGEN Pump
Biosense Webster, Inc. · Cardiac Ablation Percutaneous Catheter (LPB, Class III) · First FDA decision Sep 4, 2018, newest Mar 8, 2022Atrial fibrillation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
3
Naming "nGEN"
MAUDE reports
223
Brand "nGEN", since 2015
PubMed studies
50
Mentioning "nGEN"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing nGEN Pump
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- nGEN PumpPMA supplement
P990071-S051 · Decided Mar 8, 2022 · 251 days after receipt · Normal 180 Day Track
Device type: Cardiac ablation percutaneous catheter (LPB) · Cardiology
- nGEN PumpPMA supplement
P990071-S044 · Decided Jul 17, 2020 · 88 days after receipt · Normal 180 Day Track
Device type: Cardiac ablation percutaneous catheter (LPB) · Cardiology
- nGEN PumpPMA supplement
P990071-S037 · Decided Sep 4, 2018 · 358 days after receipt · Normal 180 Day Track
Device type: Cardiac ablation percutaneous catheter (LPB) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Cardiac Catheterization Performed In Other Than A Hospital SettingNational analysisReview closedCAG-00166NUpdated Sep 16, 2026
- Cardiac Catheterization Performed in Other than a Hospital Setting - RETIREDNational determinationOn the books20.25Updated Dec 3, 2024
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33959CGS Administrators, LLCUpdated Oct 30, 2026
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33557Wellpoint FederalUpdated Jul 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "nGEN", any status and sponsor, newest update first.
- Dual Energy Focal Ablation of Premature Ventricular ComplexesNot yet recruiting
Konstantinos SiontisAcademic, hospital or other
NCT07935265 · 60 participants (planned) · Start Jan 2027 · Primary completion Jan 2029
Device: Dual Energy THERMOCOOL SMARTTOUCH™ SF (STSF) Bi-Directional Navigation catheter with TRUPULSE™ Generator · For: Premature Ventricular Contractions
Sites: Rochester, Minnesota
Biosense Webster, Inc.Public (JNJ)
NCT04545619 · 40 participants · Start Oct 2, 2020 · Primary completion Nov 9, 2021
Device: QDOT MICRO System · For: Atrial Fibrillation
Sites: Montreal, Canada
Charles University, Czech RepublicAcademic, hospital or other
NCT06096428 · 60 participants (planned) · Start Nov 15, 2023 · Primary completion Mar 30, 2024
Device: Pulsed-field ablation; Radiofrequency ablation · For: Atrial Fibrillation; Hemolysis; Pulsed-field Ablation
Sites: Prague, Czechia
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "nGEN", and for the whole product code for context.
This brand
223 reports: 136 malfunction, 64 injury, 23 death
Whole product code LPB
14,593 reports: 5,424 malfunction, 8,535 injury, 628 death
Newest reports for this brand
- NGEN RF GENERATORInjury
3013300026-2026-03575 · Received Oct 28, 2026 · Event dated Sep 29, 2026
Device type: Cardiac Ablation Percutaneous Catheter (LPB)
Device problem as coded: Device Remains Activated; Patient Device Interaction Problem
Patient problem as coded: Atrial Fibrillation
- nGEN GeneratorMalfunction
3013300026-2026-03518 · Received Oct 22, 2026 · Event dated Sep 24, 2026
Device type: Catheter, Percutaneous, Cardiac Ablation, For Treatment Of Atrial Fibrillation (OAE)
Device problem as coded: Insufficient Heating; Patient Device Interaction Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- nGEN PumpMalfunction
3013300026-2026-03424 · Received Oct 15, 2026 · Event dated Sep 21, 2026
Device type: Cardiac Ablation Percutaneous Catheter (LPB)
Device problem as coded: No Flow
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0058-2018 · Started Sep 6, 2017
Reason given: Biosense Webster, Inc. has recently received an increased number of complaints related to the display of Alert 402 on the CARTO 3 System for certain lots of THERMOCOOL brand catheters. Alert 402 implies a "Map: magnetic distortion" when connected to CARTO 3 System. This issue may subsequently lead the physician to...
Cause as FDA categorized it: Under Investigation by firm · Device type: Cardiac Ablation Percutaneous Catheter (LPB)
Z-3178-2011 · Started Jul 7, 2011 · Posted by FDA Sep 12, 2011
Reason given: Biosense Webster has initiated a voluntary field notification to all customers that have a Stockert 70 Radio Frequency Generator, to communicate undetected software anomalies in the form of software release note in order to amend the labeling and thereby enhance the safety of the product.
Cause as FDA categorized it: Software design (manufacturing process) · Device type: Cardiac Ablation Percutaneous Catheter (LPB)
Z-1328-04 · Started Jul 16, 2004 · Posted by FDA Aug 7, 2004
Reason given: Generator Failure resulting increase of catheter temperature that could not be controlled by power reduction.
Cause as FDA categorized it: Other · Device type: Catheter, Electrode Recording, Or Probe, Electrode Recording (DRF)
Published research
The most relevant PubMed records for "nGEN"[tiab]. The summary above synthesizes these.
- Naringenin alleviates the excessive lipid deposition of polycystic ovary syndrome rats and insulin-resistant adipocytes by promoting PKGIα.
Xiang Y, Wang M, Yu G, et al. · Am J Reprod Immunol · 2023Research Support, Non-U.S. Gov't
- Cytotoxicity of naringenin induces Bax-mediated mitochondrial apoptosis in human lung adenocarcinoma A549 cells.
Lu WL, Yu CR, Lien HM, et al. · Environ Toxicol · 2020
- Naringenin Sensitizes Resistant C6 Glioma Cells with a Repressive Impact on the Migrating Ability.
J J, Vanisree AJ · Ann Neurosci · 2020
- Naringenin, a dietary flavanone, enhances insulin-like growth factor 1 receptor-mediated antioxidant defense and attenuates methylglyoxal-induced neurite damage and apoptotic death.
Tseng YT, Hsu HT, Lee TY, et al. · Nutr Neurosci · 2021
- Naringenin promote apoptosis in cerebrally implanted C6 glioma cells.
Sabarinathan D, Mahalakshmi P, Vanisree AJ · Mol Cell Biochem · 2010
- Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice.
Kanno S, Tomizawa A, Hiura T, et al. · Biol Pharm Bull · 2005Comparative Study
- Naringenin-induced apoptosis via activation of NF-kappaB and necrosis involving the loss of ATP in human promyeloleukemia HL-60 cells.
Kanno S, Tomizawa A, Ohtake T, et al. · Toxicol Lett · 2006
- Naringenin ameliorates insulin resistance by modulating endoplasmic reticulum stress in hepatitis C virus-infected liver.
Jia B, Wang Y, Yu G, et al. · Biomed Pharmacother · 2019
- Naringenin improve hepatitis C virus infection induced insulin resistance by increase PTEN expression via p53-dependent manner.
Jia B, Yu D, Yu G, et al. · Biomed Pharmacother · 2018
- Ability of naringenin, a bioflavonoid, to activate M-type potassium current in motor neuron-like cells and to increase BKCa-channel activity in HEK293T cells transfected with α-hSlo subunit.
Hsu HT, Tseng YT, Lo YC, et al. · BMC Neurosci · 2014Research Support, Non-U.S. Gov't
- Naringenin Mitigates Iron-Induced Anxiety-Like Behavioral Impairment, Mitochondrial Dysfunctions, Ectonucleotidases and Acetylcholinesterase Alteration Activities in Rat Hippocampus.
Chtourou Y, Slima AB, Gdoura R, et al. · Neurochem Res · 2015Research Support, Non-U.S. Gov't
- Mitigating Contemporary Trauma Impacts Using Ancient Applications.
Morris G, Groom R, Schuberg E, et al. · Front Psychol · 2022
Other devices of this type
Also filed under product code LPB.
- Therapy Ablation Catheter (4mm and 8mm)Irvine Biomedical, Inc. · PMA 2022
- Navistar ThermocoolBiosense Webster, Inc. · PMA 2014
- EZ Steer ThermoCool CatheterBiosense Webster, Inc. · PMA 2021
- Chilli II Cooled Ablation Catheter and CableBoston Scientific Corp · PMA 2020
- Livewire Tc Ablation Catheter, Safire Ablation CatheterSt Jude Medical · PMA 2016
- Chilli Cooled Ablation SystemBoston Scientific Corp · PMA 2011
- Blazer II Cardiac Ablation System and CableBoston Scientific Corp · PMA 2025
- Freezor Cardiac Cryoablation CatheterMedtronic Cryocath, LP · PMA 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.